SCHEDULE: Armistice Capital Discloses 9.85% Stake in Treace Medical

Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 9.85% of Treace Medical Concepts, Inc. common stock as of March 31, 2026.

Summary

• Armistice Capital, LLC, through its investment manager role, and Steven Boyd, as the managing member of Armistice Capital, have collectively reported beneficial ownership of 6,364,000 shares of Treace Medical Concepts, Inc. common stock.
• This holding represents 9.85% of the class of securities outstanding as of March 31, 2026.
• Armistice Capital exercises voting and investment power over the securities held by Armistice Capital Master Fund Ltd., the direct holder.
• The Master Fund disclaims beneficial ownership due to the investment management agreement with Armistice Capital.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it indicates a significant investment by a known entity, but provides no operational or financial performance data.

Positives

• Significant ownership stake of 9.85% indicates strong conviction from Armistice Capital in Treace Medical Concepts.
• The filing is a Schedule 13G, typically filed by passive investors, suggesting a non-activist approach to this investment.

Negatives

• The Master Fund, the direct holder, disclaims beneficial ownership, which could imply a complex ownership structure or specific investment mandates.
• No financial performance data or operational updates are included in this filing, as it is purely an ownership disclosure.

Risks

• Potential for future changes in beneficial ownership, as this is a snapshot as of a specific date.
• The nature of the investment management agreement could lead to future strategic shifts if Armistice Capital's objectives change.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding future performance. It is a disclosure of beneficial ownership.

Management Comments

• The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.

Industry Context

StockSavvy.ai notes that significant ownership disclosures by investment firms like Armistice Capital are common in the medical technology sector, often signaling a belief in the company's long-term potential or a strategic investment position.

Stakeholder Impact

• Shareholders: May view the increased institutional ownership positively, suggesting confidence in the company's prospects, but the passive nature of the filing offers no immediate strategic implications.
• Management: May need to engage with Armistice Capital on strategic matters if their investment thesis evolves, though the 13G filing suggests a passive role.
• Creditors: The filing does not directly impact creditors, but sustained institutional interest can be a positive indicator of company stability.

Next Steps

• Continued monitoring of Armistice Capital's ownership and potential future filings.
• Observation of Treace Medical Concepts' operational and financial performance to assess the impact of significant institutional holdings.

Key Dates

Keywords

Treace Medical Concepts, Armistice Capital, Schedule 13G, Beneficial Ownership, Common Stock, Investment Management, Steven Boyd, SEC Filing